FY2024
Effective from
- Title changed
- Specificity changed
- Code-level rules changed
- Inherited rules changed
Metabolic syndrome and other insulin resistance
Previous title: Metabolic syndrome
Category — select a more specific code
CDC/NCHS · FY2024codes for associated conditions
histiocytosis X (chronic) (C96.6)
Ehlers-Danlos syndromes (Q79.6-)
For US diagnosis claims covered by HIPAA, ICD-10-CM is required from October 1, 2015.
Use the service date for outpatient/professional claims and the discharge date for hospital inpatient claims. Earlier encounters use ICD-9-CM; each individual code must also be valid for the applicable date.
Official coding guidelines → · CMS ↗First observed · 2015-10-01
Latest recorded change · FY2024
Effective from
Metabolic syndrome and other insulin resistance
Previous title: Metabolic syndrome
Category — select a more specific code
CDC/NCHS · FY2024| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | Inherited rules changed |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | Inherited rules changed |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | Inherited rules changed |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | Title changed · Specificity changed · Code-level rules changed · Inherited rules changed |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Historical mapping only; not an automatic code substitution.
histiocytosis X (chronic) (C96.6)
codes for associated conditions
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Ehlers-Danlos syndromes (Q79.6-)
Other entries in the same category; these are not automatic substitutes.
| Code | Description | Category · further specificity required |
|---|---|---|
| E88.82 | Obesity due to disruption of MC4R pathway | Billable / specific |
| E88.89 | Other specified metabolic disorders | Billable / specific |
Official titles and instructions are preserved in their source language. Official sources ↗
Use additional code · code, if applicable, to identify specific condition such as insulin resistance (E88.81-)
Excludes 1 · dysmetabolic syndrome X (E88.81-)